Despite winning approvals in a range of countries like the U.S., China, Japan and Israel, Eisai and Biogen’s anti-amyloid ...

Johnson & Johnson’s latest attempt to get a handle on its talc litigation using the controversial Texas two-step bankruptcy ...

A new 42-acre campus in New Jersey gives BeiGene CEO John Oyler hope that the company can strike new partnerships in ...

After Eli Lilly’s Olumiant won the distinction of becoming the first med approved by the FDA to treat the follicle-attacking ...

Amid the sturm und drang over Inflation Reduction Act (IRA) drug price negotiations, Bristol Myers Squibb has been among the ...

AbbVie could have the hottest cancer drug launch of 2025 on its hands. | AbbVie could have the hottest cancer drug launch of ...

Among AstraZeneca’s growth drivers with $5 billion or more in peak sales potential, the company is counting on Daiichi Sankyo ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously called for a revamp of perioperative clinical trial ...

While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus (RSV) drug, the ...

Large pharma companies are still looking for deals in China. AstraZeneca and Daiichi Sankyo's antibody-drug conjugate star ...

While it may well be the dog days of summer, European drug regulators are showing no signs of slowing down in their review of ...

After making major manufacturing outlays in places like China and the United States earlier this year, Novo Nordisk is ...